Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Stroke. 2013 Oct 10;44(12):3463–3472. doi: 10.1161/STROKEAHA.111.000821

Fig 2. Autologous MNCs have the same impact on recovery and lesion size by IV or IA routes.

Fig 2

Fig 2A, B and C: Graphical representation of performance on the cylinder test (A), circling test (B) and adhesive removal test (C). Rats treated with autologous MNCs at 30 million cells/kg (high dose) achieved better neurological outcomes by IV or IA routes compared with saline controls at 28 days after stroke. However, there was no difference in outcome between the two routes. Rats treated with 1 million cells/kg showed no differences in neurological outcomes with saline controls. Higher numbers indicate more severe deficits.

Fig 2D: At 28 days after stroke, cavity size was reduced in animals treated with 30 million cells/kg of MNCs but not 1 million cells/kg. There were no differences between IV and IA routes.

Data are Means±SD. *: p< 0.05, comparing high dose IA or IV groups with saline controls. Saline Group n=18; High dosage (H-MNC) groups: H-MNCs IV n=10, H-MNCs IA n=11; low dosage (L-MNC) groups: L-MNCs IV n=9, L-MNCs IA n=9.